Clinical trial
Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma
NCT00027911 · Columbia University, Other · Terminated
Key facts
| NCT number | NCT00027911 |
|---|---|
| Title | Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma |
| Official title | A Pilot Study of NY-ESO-1 Immunization in Patients With NY-ESO-1/LAGE Antigen Expressing Cancer |
| Lead sponsor | Columbia University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Biological |
| Interventions | NY-ESO-1 peptide vaccine, sargramostim |
| Start date | Apr 1, 2001 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 15, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: